Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA on Wednesday granted accelerated ...

The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' drug, zanidatamab-hrii, for the treatment of a type of ...

Zanidatamab is the first agent approved specifically for advanced, HER2-positive second-line biliary tract cancer.

Learn more about a new treatment for biliary tract cancers with high levels of HER2. The drug zanidatamab has been approved ...

Ziihera is the first dual HER2-targeted bispecific antibody approved in the U.S. for HER2-positive biliary tract cancer ...

The agency has approved Ziihera for adults with previously treated, unresectable or metastatic HER2-positive biliary tract ...

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug.

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific antibody and chemotherapy-free treatment approved for biliary tract cancer.

Recent developments in health news highlight the CDC's anticipation of increased COVID-19 and RSV cases during the holidays, ...

Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks ...

Jazz Pharmaceuticals plc (JAZZ) announced the U.S. Food and Drug Administration accelerated approval of Ziihera (zanidatamab-hrii) ...